Pe­ter Dia­man­dis' right hand man Sergey Young wants to re­verse ag­ing via his $100M Longevi­ty Vi­sion Fund

In­spired by British bil­lion­aire Jim Mel­lon, chair­man of an­ti-ag­ing up­start biotech ven­ture Ju­ve­nes­cence, Sergey Young un­veiled a $100 mil­lion fund on Mon­day to cat­alyze the de­vel­op­ment of a com­pre­hen­sive so­lu­tion to coun­ter­act the dam­ag­ing con­se­quences of ag­ing.

“I’ve nev­er looked like my age…and with my name, I think it was pre­de­ter­mined that I was go­ing to work in the space (of ag­ing),” Young told End­points News. The 47-year-old con­sid­ers him­self a prod­uct of Pe­ter Dia­man­dis — the man be­hind the non-prof­it XPRIZE and ven­ture cap­i­tal fund BOLD Cap­i­tal Part­ners — and is in charge of all things longevi­ty at both or­ga­ni­za­tions.

Jim Mel­lon

Like Mel­lon, who penned Ju­ve­nes­cence: In­vest­ing in the Age of Longevi­ty pri­or to the launch of the com­pa­ny Ju­ve­nes­cence, Young is in the em­bry­on­ic stage of writ­ing his own book de­signed to de­code the sci­ence of ag­ing for the mass­es. Mean­while, his $100 mil­lion Longevi­ty Vi­sion Fund will back or­ga­ni­za­tions who are work­ing on tech­nol­o­gy to re­verse the ag­ing process and pro­long healthy hu­man life.

“Adding 20 to 30 healthy years on a per­son’s life is like­ly to be the largest mar­ket op­por­tu­ni­ty on earth. The con­ver­gence of Genome Se­quenc­ing, AI & Cel­lu­lar Med­i­cine will en­able break­throughs that will make 100 years old the new 60. I’m proud through our BOLD Cap­i­tal part­ner­ship to sup­port Sergey Young and the Longevi­ty Vi­sion Fund,” Pe­ter Dia­man­dis said in a state­ment.

Young did not dis­close the deals his fund is cur­rent­ly ex­plor­ing but laid out the ar­eas he is in­ter­est­ed in pur­su­ing.

Pe­ter Dia­man­dis

“We are cur­rent­ly work­ing on 6 deals…and are look­ing at all the usu­al sus­pects in terms of themes” he said. These ar­eas in­clude ear­ly de­tec­tion of se­ri­ous dis­eases us­ing ul­tra­sound tech­nol­o­gy; ear­ly di­ag­nos­tics for heart, can­cer and neu­rode­gen­er­a­tive dis­eases; stem-cell and mi­cro­bio­me-based ther­a­peu­tics; and big da­ta as well as AI-based ap­pli­ca­tions.

Un­sur­pris­ing­ly, Young is in di­a­logue with Alex Zha­voronkov’s AI shop at In­sil­i­co Med­i­cine. Zha­voronkov has deep con­nec­tions in the R&D space — last year he raised funds at the be­hest of Shang­hai high-fly­er WuXi AppTec, Sin­ga­pore’s Temasek, Pe­ter Dia­man­dis and Ju­ve­nes­cence.

“We do plan to par­tic­i­pate in the next round of fund­ing to be­come a share­hold­er of In­sil­i­co,” Young said. It is a mu­tu­al ap­pre­ci­a­tion so­ci­ety here at the Longevi­ty Lead­ers Con­gress in Lon­don, where Zha­voronkov is heard in­tro­duc­ing Young as a vi­sion­ary fund man­ag­er to a con­fer­ence at­tendee. Young, Zha­voronkov, Mel­lon and a host of oth­ers high-pro­file C-suite reg­u­lars in­volved in ag­ing R&D have flocked to a ho­tel near the renowned St Paul’s Cathe­dral to dis­cuss re­cent de­vel­op­ments in an­ti-ag­ing. In the first keynote pan­el of the day, vice pres­i­dent of Ju­ve­nes­cence-backed AgeX Aubrey de Grey am­bi­tious­ly claims that that longevi­ty space will even­tu­al­ly “dwarf the dot­com boom.”

Alex Zha­voronkov

But more fund­ing is nec­es­sary, Zha­voronkov told End­points News at the con­fer­ence. Oth­er than Google’s an­ti-ag­ing biotech Cal­i­co that has seen a large in­flux of funds, the field of an­ti-ag­ing is ripe for in­vest­ment, he said.

For long-time in­vestor and ven­ture cap­i­tal­ist Young, who has in­sight in­to the ag­ing R&D ef­fort with­in the US and to a less­er ex­tent in the UK, Chi­na and In­dia’s siz­able pop­u­la­tions pose com­pelling prospects for deals for his fund.

“In the next decade, ad­vance­ments will al­low us to be a lot more pre­dic­tive and pre­ven­ta­tive in the most dam­ag­ing dis­eases,” he said. “I’m think­ing AI-en­abled med­i­cine will em­pow­er doc­tors…tech­no­log­i­cal ad­vances to im­prove sleep­ing and med­i­ta­tion will emerge — and these are an es­sen­tial part of a healthy, long life, along with a plant-based di­et.”


Im­age: Sergey Young. LONGEVI­TY VI­SION FUND

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

→ Weeks after winning EU approval to start marketing dapagliflozin as Forxiga, AstraZeneca has racked up another OK for a triplet combo involving the SGLT2 diabetes drug. Named Qtrilmet, the pill combines Forxiga with the DPP-4 inhibitor Onglyza (saxagliptin) and the bedrock drug metformin in a modified-release format. That 3-in-1 approach proved superior in reducing average blood glucose levels to a number of other dual combinations across 5 Phase III trials, including Forxiga plus metformin, Onglyza with metformin, or glimepiride with metformin.

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

As is custom, an EMA panel on Friday issued its weekly recommendations on marketing applications submitted by drug developers. This week, the agency backed the use of five new therapies — including two Novartis drugs — but issued no negative reviews.

Novartis’ S1P drug for relapsing forms of multiple sclerosis (MS) drug, Mayzent (known chemically as siponimod), which was approved by the FDA in March — has been given the nod by the EMA. The Swiss drugmaker already sells its other MS drug, Gilenya, in both regions.

Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

The folks behind Atomwise’s spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures to back those missions.

X-37 uses Atomwise’s AI platform to identify drug targets and – unlike the parent company, which largely sticks to computers  – bring those into a wet lab and preclinical testing.  In addition to AI professionals, it’s led in by part by drug developers from Velocity Pharmaceutical Development.

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

→ Abbott Laboratories has named a successor to CEO Miles White after he announced that he was stepping down in March after 21 years of service. Robert Ford, the company’s COO and president, will take the helm. Ford is known for his work in the $25 billion merger between St. Jude Medical into Abbott in January 2017. White will remain with the company as executive chairman of the board. 

→ After snapping up Novartis’ Swiss facility, Novartis Center of Excellence, in July, Lonza has announced that their CEO, Marc Funk, is hitting the exit for “personal reasons.” Funk has been the CEO of the company for less than a year — brought onto the company back in March. In the meantime, chairman Albert Baehny will serve as interim CEO. 

UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

A month after posting positive top-line data from their first Phase III trial of the IL-17A/17F inhibitor bimekizumab, Belgium’s UCB says they’ve added more upbeat results from their second late-stage test in moderate-to-severe plaque psoriasis.

That leaves the company on track for regulatory submissions in the middle of next year, says CMO Iris Loew-Friedrich.
Their drug beat out a placebo on the co-primaries — a 90% improvement in PASI 90 (the Psoriasis Area and Severity Index) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1) at week 16, compared to placebo. Investigators also boasted of hitting some key secondaries.
UCB is angling to enter an increasingly crowded market space.
In their first of 3 Phase III studies for bimekizumab, researchers touted top-line wins on statistically significant results on clearing plaque psoriasis, including a victory over J&J’s IL-23 contender Stelara on key endpoints. The drug targets both IL-17A and IL-17F, a modification on the IL-17A strategy laid out for Taltz (Eli Lilly) and Cosentyx (Novartis). And the new group also includes J&J’s Tremfya and AbbVie’s Skyrizi.

Social image: UCB